VKTX Viking Therapeutics, Inc.Stock Price & Overview
$76.97
Charts
Quant Ranking
VKTX Analysis
VKTX News
Latest Headlines
Ratings Summary
People Also Follow
Similar to VKTX
ETFs Holding VKTX
VKTX Company Profile
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
VKTX Revenue
VKTX Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Profitability
Momentum
Capital Structure
Dividends
VKTX Ownership
VKTX Peers
Risk
Technicals
VKTX Transcripts
Investor Presentations
VKTX SEC Filings
Press Releases
VKTX Income Statement
VKTX Balance Sheet
VKTX Cash Flow Statement
VKTX Long Term Solvency
Discover More
You may be interested in: